Author: admin

Recent Congressional debate over federal funding shuttered a critical pipeline that feeds American biotechnology innovation. On November 17, 2025, the National Institutes of Health (NIH) released a short notice to the research community that the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program had expired, “effective immediately.” The SBIR/STTR program funds small business innovations across the federal government, including the Departments of Agriculture, Commerce, Energy, Health and Human Services, and Defense. All these agencies’ SBIR/STTR programs have gone dark. This is a very big deal—companies will fail and the benefits of their innovations will remain…

As we enter 2026, this is an opportune moment to look back at the latest scientific and medical advances in gut microbiome research during the past year. This ‘Year in Review’ article delves into key developments of gut microbiome research of 2025, organized by thematic areas to highlight emerging patterns and connections across scientific disciplines.   Compounds made by gut bacteria could point to therapeutic avenues to protect against cardiovascular disease The gut microbiome is important for metabolic health. Studies in 2025 have revealed mechanisms by which key gut microbial metabolites promote plaque build-up in arteries and prevent fat accumulation…

This postdoc focuses on addressing long-standing gaps in research, education, and patient care for individuals with rare genetic disorders.Image credit:Solanch Dupeyron, ©iStock.com, Liudmila ChernetskaQ | Write a brief introduction to yourself including the lab you work in and your research background. My name is Jessica Strosahl, and I am a Postdoctoral Fellow and Genetic Metabolic Dietitian under the mentorship of Rani Singh in the Department of Human Genetics at Emory University. I work within the Medical Nutrition Therapy for Prevention Program, which addresses critical gaps in research, education, and patient care for individuals with inherited metabolic disorders (IMDs) and other…

With a revived bull market allowing biopharma giants to set aside more capital for merger-and-acquisition (M&A) deals over the past year, 2026 will likely see an increase in the number as well as dollar value of such transactions, according to a report released to coincide with the 43rd Annual J.P. Morgan Healthcare Conference. But the M&A surge will not significantly lift initial public offerings (IPOs) out of the doldrums. EY—the professional services firm once known as Ernst & Young—reported a 23% jump in the amount of capital or “firepower” set aside for dealmaking by the top 25 biopharmas, to $1.6…

Phase 1b results for GT-02287 point to biological impact in Parkinson’s, strengthening the case for disease-modifying approaches. Progress in Parkinson’s disease has been judged largely by visible symptoms. Tremors, rigidity, gait changes have been the bellwethers for decades. Beneath those outward signs is a quieter story, one unfolding at the cellular level, where aging neurons struggle to clear toxic buildup and maintain energy balance. New data from AI-powered biotech Gain Therapeutics suggest that the story may finally be measurable and possibly alterable. In its latest update from a Phase 1b clinical study, Gain Therapeutics reports biomarker evidence that its lead…

Many of us will recognize being in a situation where it’s really hard to get started on a task—whether it’s making a difficult phone call or preparing a presentation that’s stressful just to think about. We understand what needs to be done, yet taking that very first step feels surprisingly hard. When this difficulty becomes severe, it is known medically as avolition. People with avolition are not lazy or unaware. They know what they need to do, but their brains seem unable to push the “go” button. Avolition is commonly seen in conditions such as depression, schizophrenia, and Parkinson’s disease,…

ORI typically releases an average of about 10 research misconduct findings a year. In 2025, they released two.Image credit:© iStock.com, sesameThe U.S. Office of Research Integrity has been relatively quiet in 2025, releasing just two misconduct findings with only two weeks remaining in the year — the fewest the office has released since at least 2006. ORI typically releases an average of about 10 findings a year. The office, part of the Department of Health and Human Services, oversees research integrity and misconduct for the National Institutes of Health, the Centers for Disease Control and Prevention and other HHS agencies.…

NRG Therapeutics takes a first-in-human step toward disease-modifying treatments for ALS and Parkinson’s, targeting aging at cellular level. There are clinical trial announcements that feel routine, and then there are those that quietly redraw the map of where medicine is heading. UK-based clinical-stage neuroscience company NRG Therapeutics has completed its first-in-human dosing of NRG5051, which belongs firmly in the latter category. The company has begun its Phase 1 clinical trial of NRG5051, an experimental drug designed to slow or potentially halt the progression of ALS/MND and Parkinson’s by targeting a shared biological weak point: mitochondrial failure [1]. It is a…

A map of the immune cell landscape found in the bone marrow of patients with multiple myeloma could shed light on how the immune system interacts with cancerous plasma cells. It could also help scientists determine how aggressive a patient’s cancer is likely to be, as well as drive the development of more effective immune-based therapies.   The map is the subject of a new Nature Cancer paper titled “A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.” The study was done by a group of scientists from multiple institutions, including Washington…

View eBook The landscape of proteomics technologies has traditionally been defined by trade offs between coverage—the ability to detect many proteins—and detail—the ability to confidently measure the abundance of every detected protein as well as the ability to quantify proteoforms. In this eBook, we explore the pros and cons of emerging and traditional proteomics technologies in terms of coverage and detail. Furthermore, we discuss how the NautilusTM Proteome Analysis Platform is designed to employ a novel proteomic analysis method called Iterative Mapping to overcome tradeoffs between coverage and detail and deliver a complete proteomics solution. Previous articleCellares and City of…